Key facts
- This page summarizes Patrick Baeuerle's Form 4 filing for Cullinan Oncology, Inc. (CGEM).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 26 Aug 2021, 19:11.
Patrick Baeuerle - 10 Aug 2021 Form 4 Insider Report for Cullinan Oncology, Inc. (CGEM)
- Reporting relationship
- Acting Chief Scientific Officer, Biologics
- Issuer ticker
- CGEM
- Reported as of
- 10 Aug 2021
- Net transaction value
- -$249,700
- SEC form
- 4
- Accepted by SEC
- 26 Aug 2021, 19:11:47 UTC
- Next SEC filing
- 09 Sep 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jeffrey Trigilio, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Patrick Baeuerle filed Form 4 for Cullinan Oncology, Inc. (CGEM) on 26 Aug 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: -$249,700.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CGEM
transaction
Common Stock
Options Exercise
- Transaction value
- $47,300
- Shares
- +11,000
- Change %
- Price
- $4.30
- Shares after
- 11,000
- Date
- 10 Aug 2021
- Ownership
- Direct
CGEM
transaction
Common Stock
Sale
- Transaction value
- $297,000
- Shares
- -11,000
- Change %
- -100%
- Price
- $27.00
- Shares after
- 0
- Date
- 10 Aug 2021
- Ownership
- Direct
- Footnotes
- F1
CGEM
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 341,434
- Date
- 10 Aug 2021
- Ownership
- See Footnote
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CGEM
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- $0
- Shares
- -11,000
- Change %
- -4.2%
- Price
- $0.000000
- Shares after
- 251,114
- Date
- 10 Aug 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 11,000
- Exercise price
- $4.30
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 30, 2021.
Footnote F2
Shares held directly by APAK Solutions GmbH. The Reporting Person is managing director of APAK Solutions GmbH. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
Footnote F3
25% of the shares vested on September 1, 2019, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
SEC remarks
Acting Chief Scientific Officer, Biologics